Evaluation of bioequivalence of five 0.1 mg dutasteride capsules compared to one 0.5 mg dutasteride capsule: a randomized study in healthy male volunteers

Michael J. FosslerClinical Pharmacology Modeling and Simulation, Quantitative Sciences, GlaxoSmithKline, King of Prussia, PA, USA

David A. CollinsClinical Statistics, Quantitative Sciences, GlaxoSmithKline, Research Triangle Park, NC, USA

Hiroko InoMedicines Development (Immuno-Inflammation), Development & Medical Affairs Division, GlaxoSmithKline K.K., Tokyo, JapanCorrespondence[email protected]

Nobuaki SaraiMedicines Development (Immuno-Inflammation), Development & Medical Affairs Division, GlaxoSmithKline K.K., Tokyo, Japan

Ramiya RavindranathStatistics and Programming, Quantitative Sciences, GlaxoSmithKline, Bangalore, India

Chester L. BowenDrug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, PA, USA

Olivia BurnsClinical Pharmacology Science and Study Operations, GlaxoSmithKline Australia Pty Ltd, Abbotsford, Victoria, Australia

show all

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Evaluation of bioequivalence of five 0.1 mg dutasteride capsules compared to one 0.5 mg dutasteride capsule: a randomized study in healthy male volunteers

Articles from other publishers (3)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Evaluation of bioequivalence of five 0.1 mg dutasteride capsules compared to one 0.5 mg dutasteride capsule: a randomized study in healthy male volunteers

Citations (3)

Articles from other publishers (3)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date